Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
01 dec 2006 - 08:08
Statutaire naam
Crucell N.V.
Titel
Crucell Awarded Contracts of Over $230 Million for Quinvaxem™ and Hepavax-Gene® Vaccines
Bericht
PRESS RELEASE
Crucell Awarded Contracts of Over $230 Million for
Quinvaxem™ and Hepavax-Gene® Vaccines
Leiden, The Netherlands, December 1, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has been awarded contracts totaling over US $230 million for its Quinvaxem™ and Hepavax-Gene® paediatric vaccines by supranational organizations. The contracts cover the next three years until 2009, with the awarded amount growing over those three years.
Following the WHO prequalification in September 2006 the combination vaccine was made available to supranational purchasing organizations. Supranational organizations are major customers for combination vaccines, which are used in large vaccination programs in developing countries.
Quinvaxem™, a fully-liquid pentavalent vaccine for children, was co-developed with Novartis Vaccines and Diagnostics and is produced in Crucell’s laboratories in South Korea. The vaccine combines antigens for protection against five important childhood diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b, one of the leading causes of bacterial meningitis and pneumonia in children.
Current demand for the Quinvaxem® vaccine exceeds 50 million doses. The total market potential is 150 million doses per year in 3 to 4 years.
The Hepavax-Gene®, recombinant hepatitis B vaccine, is one of the WHO’s pre-qualified vaccines for active immunization against the hepatitis B virus. Young children infected with HBV are the most likely to develop chronic infections. Hepavax-Gene® was internationally introduced in 1996 and has become one of today’s major hepatitis B vaccines supplied to more than 90 countries.
“The multiple year contracts that the supranational organizations have granted to Crucell, underline Crucell’s position as a leading supplier of important vaccines. Quinvaxem™ is the first internationally available fully-liquid vaccine
Datum laatste update: 28 juli 2024